Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China

Daiichi Sankyo1,271 enrolled

Overview

The aim of this study is to investigate the pharmacological treatment pattern among patients with diabetic peripheral neuropathic pain (DPNP) and chemotherapy-induced peripheral neuropathy (CIPN) in China.

Diabetic peripheral neuropathic pain (DPNP) and chemotherapy-induced peripheral neuropathy (CIPN) are common subtypes of neuropathic pain. The treatment pattern, subsequent medication usage, and adherence information of medication among these patients are still not clear. There is also an unmet need for the use of relevant analgesic medications in this area. This real-world data study aims to understand patients' characteristics, clinical diagnosis and treatment patterns, medication adherence, real-world effectiveness among DPNP and CIPN patients in China and will explore the current unmet needs of DPNP and CIPN, in order to inform physicians' decision-making in clinical practice

Study Type

OBSERVATIONAL

Enrollment

1,271

Conditions

Diabetic Peripheral Neuropathic Pain Chemotherapy-induced Peripheral Neuropathy Neuropathic Pain

Interventions

No DrugOTHER

This is an non-interventional, observational study. No drug was administered during this study.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Participants who meet all the following criteria will be included in the DPNP cohort. 1. Participants were diagnosed with diabetic neuropathy and presented with the pain symptom between 1st January 2018 and 31st December 2021; 2. Participants received at least one targeted medication between 1st January 2018 and 31st December 2021; 3. Participants were ≥18 years on the index date; 4. Participants had at least one medical visit record within 12 months after the index date Participants who meet any one of the following criteria will be excluded from the DPNP cohort. (1) Participants were diagnosed with epilepsy, schizophrenia, or bipolar disorder before or on the index date Participants who meet all the following criteria will be included in the CIPN cohort. 1. Participants had neuropathy that was induced by the chemotherapy between 1st January 2018 and 31st December 2021, regardless of the presence of pain symptoms; 2. Participants received at least one targeted medication between 1st January 2018 and 31st December 2021; 3. Participants were ≥18 years on the index date; 4. Participants had at least one medical visit record within12 months after the index date Participants who meet any one of the following criteria will be excluded from the CIPN cohort. 1. Participants were diagnosed with epilepsy, schizophrenia, or bipolar disorder before or on the index date; 2. Participants had neuralgia or neuropathy caused by tumor metastasis or non-chemotherapy-induced factors (e.g., radiotherapy, myasthenia gravis syndrome, paraneoplastic syndrome, direct tumor invasion, local tissue compression, postoperative traumatic pain, immune therapy-related pain, comorbidity-induced pain, etc.)

Locations (10)

China-Japan Friendship Hospital

Beijing, China

Beijing Hospital

Beijing, China

Beijing Cancer Hospital

Beijing, China

Outcomes

Primary Outcomes

Proportion of participants receiving different treatment regimens (targeted medications or combinations) and related medication categories in participants with DPNP or CIPN

The treatment regimen will be evaluated and confirmed as monotherapy or combination therapy based on prescription records at each visit. Monotherapy is defined as participants only received one targeted medication. Combination therapy is defined as participants received more than one targeted medication at the same time.

Time frame: From index date up to 31st December 2022

Proportion of participants who discontinue/switch/add-on treatment and related medication categories in participants with DPNP or CIPN

Treatment discontinuation is defined as the time interval between two adjacent treatment regimens, or the time interval between the end of the last treatment regimen and the study end date (31st December 2022), or the time interval between the end of the last treatment regimen and the date of death is ≥90 days. Treatment switch is defined as the change of treatment regimen, either in monotherapy or in combination (exclude treatment add-on). Treatment add-on is defined as the addition of one or more targeted medications to an existing treatment regimen (monotherapy or combination therapy).

Time frame: From index date up to 31st December 2022

Proportion of participants who restarted treatment after discontinuation in participants with DPNP or CIPN

Among those who had discontinued treatment, the proportion of patients who received at least one targeted medication at the next visit will be assessed, where the treatment regimen containing the targeted medication includes the same treatment medication prior to discontinuation or a different treatment medication after treatment switch/add-on.

Time frame: From index date up to 31st December 2022

Duration of the current treatment in participants with DPNP or CIPN

Duration of the current treatment is defined as the time interval from the start date of a treatment to its end date. The end date of the treatment refers to its discontinuation date; for participants who did not experience a treatment discontinuation, the end date of treatment prescription is used.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Initial daily dose in participants with DPNP or CIPN

Initial daily dose is defined as the first prescribed daily dose of the targeted medications.

Time frame: From index date up to 31st December 2022

Maximum daily dose in participants with DPNP or CIPN

Maximum daily dose is defined as the maximum of the daily dose.

Time frame: From index date up to 31st December 2022

Time to the maximum daily dose in participants with DPNP or CIPN

Time to the maximum daily dose is defined as the time interval between the daily dose to the maximum daily dose.

Time frame: From index date up to 31st December 2022

Proportion of participants who underwent the daily dose change in participants with DPNP or CIPN

Proportion of participants who underwent the daily dose change is defined as the proportion of participants who underwent the dose changes from the initial daily dose to 2 weeks, 4 weeks and 6 weeks, respectively.

Time frame: From index date up to 31st December 2022